Title: Glycans at the Frontiers of Inflammation, Autoimmunity and Cancer: mechanisms and clinical implications.
Salomé Pinho is the coordinator of the research group "Immunology, Cancer & GlycoMedicine" at the Institute for Research and Innovation in Health (i3S) at the University of Porto, Portugal, and affiliated Professor at the Medical Faculty of the University of Porto, Portugal. She developed her Ph.D. research at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Boston University Medical School, MA, USA. She performed her postdoctoral work at IPATIMUP-University of Porto in the cancer glycobiology field. Early in her career, Dr. Pinho established a research line focusing on glycoimmunology in Inflammatory Bowel Disease. Her group focuses on understanding the role of post-translational modifications by glycosylation in the regulation of key proteins´ functions involved in cancer and chronic inflammatory conditions, envisioning potential clinical applications.
She is the Principal Investigator of several national/international grants in cancer glycobiology and inflammatory diseases. She received the Young Investigator Award from the European Association for Cancer Research and was recently distinguished by the Society for Glycobiology with the 2020 Glycobiology Significant Achievement Award.
Title: Probing Specific Interactions of Synthetic Heparan Sulfate Saccharides and Disease-Related Proteins
Professor Shang-Cheng Hung received his Ph.D. in Chemistry from the National Tsing Hua University, Taiwan (1992). He did postdoctoral research with Professor Andrew Streitwieser at the University of California at Berkeley (1994-1995) and Professor Chi-Huey Wong at The Scripps Research Institute (1995-1998). Professor Hung started independent research at the Institute of Chemistry, Academia Sinica, in 1998 and moved to the Department of Chemistry, National TsingHua University, in 2005. In 2009, he moved back to Taipei and joined the Genomics Research Center, Academia Sinica, where he was promoted to Distinguished Professor in 2012. His research interests aim to develop new strategies for synthesizing complex carbohydrates such as glycosaminoglycans and sialo-sugars on the cell surface to probe their specific interactions with disease-associated proteins.
Title: Desialylation GlycoSwitch to Acutely Control Endocytosis
Professor Ludger Johannes is Research Director (DRE) at INSERM. He is a member of the Studienstiftung des Deutschen Volkes (German organization of the academically gifted), Boehringer Ingelheim Fonds, European Molecular Biology Organization (EMBO), and German Academy of Science — Leopoldina. At Institut Curie, he has been heading since 2001 the Traffic, Signaling, and Delivery Team, member of the excellence initiative Cell(n)Scale. Since January 2014, he has directed the Cellular and Chemical Biology unit. His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking. The Johannes team has discovered the membrane trafficking interface between early endosomes and the Golgi apparatus, and demonstrated that lectin-induced glycolipid reorganization acts as a driving force in clathrin-independent endocytosis (termed the GlycoLipid-Lectin / GL-Lect hypothesis). The studies of the Johannes team have been published in highly visible international journals, including Cell and Nature. Between 2014-2020, he was the holder of an ERC advanced grant. He also aims at exploiting the discoveries of his team for the development of innovative cancer therapy strategies using the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy.
Title: Regulation and Protein Selectivity of N-Glycan Branching Enzymes
Professor Yasuhiko Kizuka has been a researcher at Disease Glycomics Team, RIKEN, led by Dr. Naoyuki Taniguchi (2009-2017). He has joined Gifu University (Japan) as an Associate Professor since 2017, and is currently the Director and Professor of Integrated Glyco-Molecular Science Center, Institute for Glyco-core Research (iGCORE) at Gifu University.
Professor Kizuka’s glyco-related contributions include discovery of novel mode of catalytic action of glycosyltransferases, elucidation of glycosyltransferase structures and development of glycosyltransferase inhibitors. His Research Interests are (1) Regulation of glycosyltransferase activity; (2) Substrate protein selectivity of glycosyltransferases; (3) Physiological functions of N-glycan branches.
Title: Making weak antigens strong: exploiting bacterial outer membrane vesicles for delivering glycans to the immune system
Professor Matthew P. DeLisa is the William L. Lewis Professor of Engineering in the School of Chemical and Biomolecular Engineering at Cornell University. His research focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis--folding and assembly, membrane translocation, and post-translational modifications--in the complex environment of a living cell. He received a B.S. in Chemical Engineering from the University of Connecticut in 1996; a Ph.D. in Chemical Engineering from the University of Maryland in 2001; and postdoctoral work at the University of Texas-Austin, Department of Chemical Engineering. DeLisa joined the Department of Chemical and Biomolecular Engineering at Cornell University in 2003. He has also served as a Gastprofessur at the Swiss Federal Institute of Technology (ETH Zürich) in the Institut für Mikrobiologie. He has garnered a number of honors and awards, including most recently the Biotechnology Progress Award for Excellence in Biological Engineering Publication, and was named the to the inaugural “Life Sciences Power 50” by City & State New York. He is an elected fellow of the American Institute for Medical and Biological Engineering, the American Academy of Microbiology, and the American Association for the Advancement of Science. In recent years, he has served on the IDA/DARPA Defense Science Study Group and the National Academies Committee on Innovative Technologies to Advance Pharmaceutical Manufacturing.
Professor Yasuhiro Kajihara received his Ph.D. from the Tokyo Institute of Technology in 1993. He spent two years at the Life Science Research Laboratory of Japan Tobacco Inc. as a postdoctoral fellow. In 1995 he joined Yokohama City University as an assistant professor and was then promoted to associate professor in 2001 and full professor in 2007. At YCU, he developed synthetic methods for oligosaccharides and glycoproteins. In 2009, he moved to the Department of Chemistry at Osaka University. He studies new synthetic methods of glycoproteins in order to understand how oligosaccharides regulate protein functions.
Title: From mucin-type O-glycans to bacterial polysaccharides
Inka Brockhausen received her Ph.D. in Biochemistry at the University of Toronto, Canada. At Toronto’s Hospital for Sick Children, she studied both structures and biosynthesis of O-and N-glycans and discovered a number of novel enzymes in the O- and N-glycosylation pathways. As an associate professor at the University of Toronto, her research interest focused on structural and enzymatic glycosylation abnormalities in cancer and cystic fibrosis. Further studies on the link between glycosylation changes in arthritis and inflammatory conditions were carried out at Queen’s University, Kingston, Canada. A major interest became the discovery of novel glycosyltransferases in bacteria, in collaboration with synthetic chemists, e.g., Walter Szarek, Ole Hindsgaul, Vladimir Torgov, and others that were instrumental in the synthesis of natural substrate analogs. Glycosylation inhibitors were developed that could alter the biological properties of cells or could be anti-bacterial compounds. Current directions in the Brockhausen lab at the Department of Biomedical and Molecular Sciences aim to understand polysaccharide synthesis in bacteria and fungi and the mechanisms of enzymes involved in carbohydrate metabolism. Brockhausen also has a keen interest in protein aggregation in neurodegeneration and is a member of the Centre for Neuroscience Studies.
Title: Human Gut Bacteria Tailor Extracellular Vesicle Cargo for the Breakdown of Diet- and host-derived glycans
Dr. Feldman obtained his Ph.D. at the University of Buenos Aires, Argentina, under the supervision of Dr. Armando Parodi. After completing his postdoctoral training in Guy Cornelis and Markus Aebi labs in Switzerland, he joined the University of Alberta, in Edmonton, Canada, as an assistant professor. In 2015 he moved to the Department of Microbiology at the Washington University School of Medicine in St Louis, USA. The Feldman lab is interested in microbial glycobiology and bacterial pathogenesis. Dr. Feldman has pioneered the field of bacterial glycoengineering, which is a promising approach for the generation of novel bioconjugate vaccines. He has co-founded two companies (VaxAlta and Omniose) in this area. He is a world leader in studying the human pathogen Acinetobacter baumannii and the biogenesis of bacterial extracellular vesicles. Dr. Feldman is a fellow of the American Academy of Microbiology.
Title: Systems Level Studies of Viral Infection: Roles for Site-specific Glycosylation, Biochemical Pathways and Intracellular Lectins
Dr. Sriram Neelamegham is a UB Distinguished Professor of Chemical & Biological Engineering, Biomedical Engineering, and Medicine at the State University of New York-Buffalo. His laboratory works at the interface of engineering and medicine, with applications in studies of human disease mechanics. Such work falls under the umbrella of "Systems Glycobiology," where high-throughput experimentation and mathematical modeling are coupled to describe the interplay between the competing glycoEnzymes that regulate cellular glycosylation patterns. Prof. Neelamegham has published over 140 research articles, book chapters, and patents. He receives the NIH Independent Scientist award, the 2015 State University of New York Chancellor's Award for Excellence in Scholarship and Creative Activities, and the 2018 Schoellkopf medal from the Western New York American Chemical Society. He is an Elected Fellow of the American Institute of Biological and Medical Engineering (AIMBE) and Biomedical Engineering Society (BMES). He has served on NIH advisory panels and editorial boards of various journals. He is currently the Discussion Leader developing the Symbol Nomenclature for Glycans (SNFG) at the NCBI-glycans resource. Before moving to Buffalo. Prof. Neelamegham received his Ph.D. in Chemical Engineering/Bioengineering from the Rice University and completed his post-doctoral training at the Baylor College of Medicine.
Title: An interface is worth a thousand pictures: An integrated systems approach to glycobiology
Dr. Daniel Bojar is a tenure-track assistant professor at the Wallenberg Centre for Molecular and Translational Medicine & the Department of Chemistry and Molecular Biology at the University of Gothenburg in Sweden, focusing on machine learning and data science in the field of glycobiology. He obtained his Ph.D. in mammalian synthetic biology at ETH Zurich and continued his postdoctoral training in computational biology at MIT & Harvard University. His group develops and applies methods to discover sequence-to-function associations and biological roles of glycans via a broad set of approaches from machine learning, data science, and bioinformatics. Daniel was awarded a Branco Weiss Fellowship - Society in Science, as well as a Foresight Fellowship, and was recognized as a "Rising Star" by the journal Advanced Science. He was also featured on the 2022 Forbes 30 Under 30 Europe list for work in Science & Healthcare.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.
Title: Glycan: A Target for Diagnosis and Treatment of Brain Tumors
Professor Atit Silsirivanit received his Ph.D. in Medical Biochemistry from Khon Kaen University in 2011. During 2014-2016, he was supported by the Japan Society for the Promotion of Science (JSPS) to pursue postdoctoral training at the Department of Tumor Genetics and Biology, Kumamoto University, Japan. His current position is as an Associate Professor of Biochemistry at the Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Thailand. His research focuses on the involvement of glycans and glycosylation in the development and progression of cancers, including cholangiocarcinoma, glioblastoma, meningioma, and melanoma. We are currently working on 1) The role of glycans and glycosylation in cancer, 2) Identification of glycobiomarkers for cancer diagnosis, monitoring, and prognostic prediction, and 3) Application of lectins for detection of glycobiomarkers.
Professor Tadashi Suzuki received his Ph.D. (1997) from Department of Biochemistry and Biophysics at University of Tokyo, Japan. He demonstrated the activity and characterized the enzymatic properties of the cytoplasmic peptide:N-glycanase (PNGase/Ngly1) mammalian cells and proposed that this enzyme may be involved in the quality control of newly synthesized glycoproteins. Dr. Suzuki was a postdoctoral fellow at Department of Biochemistry and Cell Biology, State University of New York at Stony Brook (1997-2000). He was an Assistant Professor at University of Tokyo (2002-2004) and a Visiting Associate Professor at Osaka University Graduate School of Medicine (2004-2007). During this period, he identified two cytoplasmic glycosidases, endo-beta-N-acetylglucosaminidase (ENGase) and alpha-mannosidase (Man2C1), involved in the catabolism of free glycans released by the cytoplasmic PNGase. He was a Team Leader at Glycometabolome Team, Systems Glycobiology Research Group, RIKEN. He currently serves as a Chief Scientist at Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research.
His current research interests are (1) clarification of the novel catabolic pathway for glycans on glycoproteins; (2) characterization of biological functions of cytoplasmic peptide:N-glycanase (Ngly1) for the non-lysosomal catabolic pathway of N-glycans; (3) development of new analytical methods for glycans; and (4) development of therapeutics for NGLY1-deficiency.